Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

• Status: Completed
• Trial end date: 2017-03-03
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Imatinib is safe and effective in association with intensive treatment of Ph+ALL in children.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rennes University Hospital
• Collaborators: Ministry of Health, France; Novartis
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• Children and adolescents aged 1 to 17 years at diagnostic

• Documented Ph+ ALL

• Eligibility for the current local prospective therapeutic study of childhood ALL

• Informed consent given by the parents or by legal guardian

Exclusion Criteria:

• Abnormal hepatic functions

• Abnormal renal functions

• Active systemic bacterial, fungal or viral infection